Skip to content
Biotechnology

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

The BioMed X Institute 3 mins read

A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

RIDGEFIELD, CT / ACCESSWIRE / May 16, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.



The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."

Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."

"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.

"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.

About BioMed X and XSeed Labs

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27

Related Images

SOURCE: BioMed X Institute & XSeed Labs

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 07/06/2024
  • 06:00
Centre for Eye Research Australia. Bionics Institute. Bionic Vision Technologies

Bionic eye trial reveals substantial vision improvements over two and a half years

Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years. Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, are published in Ophthalmology Science. The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye…

  • Biotechnology, Results Statistics
  • 31/05/2024
  • 07:54
The Lottery Corporation Ltd

Powerball Draw no. 1463

Official Results Powerball Draw no. 1463 Draw Date: Thursday, 30 May 2024 Drawn Numbers Winning Numbers 35 2 3 33 20 22 10 (drawn order) Powerball 9 Dividends Dividends Total Winners Total Prizes Payable Division 1 $0.00 0 $0.00 Division 2 $270,217.65 1 $270,217.65 Division 3 $9,598.45 35 $335,945.75 Division 4 $571.70 511 $292,138.70 Division 5 $192.00 1,141 $219,072.00 Division 6 $79.50 17,268 $1,372,806.00 Division 7 $49.50 21,547 $1,066,576.50 Division 8 $20.30 111,436 $2,262,150.80 Division 9 $11.90 326,742 $3,888,229.80 478,681 $9,707,137.20 Division 1 Jackpots to $12,000,000.00

  • Contains:
  • Biotechnology
  • 30/05/2024
  • 20:07
Moolec Science SA

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

LUXEMBOURG / ACCESSWIRE / May 30, 2024 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.Moolec Science Logo The main highlights of Moolec's business update are as follows:Piggy Sooy™ Product | Soybean Platform: Moolec's patented soybean product received USDA-APHIS Regulatory Status Review approval in April 2024.Safflower Platform: GLASO™ planting campaign progressing as expected. Two US Patents granted for production of chymosin in safflower seeds (SPC2) extended exclusive technology protection until 2041.Financial…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.